The Petri Dish: Takeda scores win from Nimbus licensing deal; Biogen exits partnership
Takeda paid Nimbus Therapeutics $4 billion for a psoriasis drug in December. It just met its primary goal in a midstage trial. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - March 23, 2023 Category: Health Management Authors: Rowan Walrath Source Type: news
Smoking Independently Tied to Higher Risk for Psoriasis
TUESDAY, March 21, 2023 -- Smoking is tied to an increased risk for psoriasis, but may not be a cause of psoriasis, according to a study published online Feb. 22 in Frontiers in Immunology.
Charlotte Näslund-Koch, from Copenhagen University... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 21, 2023 Category: Pharmaceuticals Source Type: news
High Rates of Psoriasis Clearance With Investigational TYK2 Inhibitor
(MedPage Today) -- NEW ORLEANS -- As many as a third of patients with moderate or severe psoriasis had complete clearance within 12 weeks with an investigational oral tyrosine kinase 2 (TYK2) inhibitor, a small randomized trial showed.
From... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - March 21, 2023 Category: Dermatology Source Type: news
Planning for a Pregnancy? Don't Let Eczema, Psoriasis Get in the Way
MONDAY, March 20, 2023 -- During pregnancy, women may need to consider different options for treating certain health issues.
The American Academy of Dermatology (AAD) offers some suggestions for pregnant women living with the common skin conditions... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 20, 2023 Category: General Medicine Source Type: news
Biologic Switch Revs Up Response in Plaque Psoriasis
(MedPage Today) -- NEW ORLEANS -- Plaque psoriasis that responded inadequately to an interleukin (IL)-17 inhibitor often had deep and durable responses after switching to the IL-23 inhibitor risankizumab (Skyrizi), a long-term prospective trial... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - March 19, 2023 Category: Dermatology Source Type: news
‘We’ll look back and say that this was a bargain.’ Takeda reveals first data from its $4 billion autoimmune disease pill
In an intermediate-stage clinical study of 259 people with moderate-to-severe plaque psoriasis, the highest dose of the daily pill completely cleared itchy and painful patches of skin in one-third of the patients after 12 weeks. “We’re offering the potential for a functional cure,” Andrew Plump,…#andrewplump #takeda #boston #nimbustherapeutics #neworleans #plump #crohns #nimbus #tyk2 #bristolmyerssquibb (Source: Reuters: Health)
Source: Reuters: Health - March 18, 2023 Category: Consumer Health News Source Type: news
TREMFYA ® (guselkumab) Real-World Data Analyses Show Greater Treatment Persistence Than IL-17s in Both Bio-naïve and Bio-experienced Patients Living With Moderate to Severe Plaque Psoriasis
SPRING HOUSE, PENNSYLVANIA, March 17, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data, showing that initiation of TREMFYA® (guselkumab) was associated with greater treatment persistencea compared to secukinumab or ixekizumab in bio-naïve and bio-experienced patientsb living with moderate to severe plaque psoriasis (PsO), based on pairwise analysesc of real-world data.[1],[2] Additionally, in a post-hoc analysis of Phase 3 VOYAGE 2 clinical trial results, TREMFYA demonstrated durable clinical efficacy, itch relief and quality-of-life improvements in patients living with scal...
Source: Johnson and Johnson - March 17, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Eli Lilly forays into dermatological space with launch of psoriasis drug
Eli Lilly has launched a new drug to treat moderate-to-severe plaque psoriasis in India. The drug, Copellor, is designed to specifically target a protein that plays a role in triggering and maintaining inflammation in psoriasis. Copellor is a prescription medicine that is only to be used on the advice of a dermatologist or rheumatologist and under medical supervision. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 14, 2023 Category: Pharmaceuticals Source Type: news
Biologics May Delay Arthritis in Psoriasis Patients Biologics May Delay Arthritis in Psoriasis Patients
Treatment with the interleukin-12/23 inhibitor ustekinumab or interleukin-23 inhibitors was linked to a lower risk of developing psoriatic arthritis compared with tumor necrosis factor inhibitors.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - March 9, 2023 Category: Dermatology Tags: Rheumatology News Source Type: news
New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
TREMFYA ® (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab in In Vitro Studies
SPRING HOUSE, PENNSYLVANIA, March 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced additional results from in vitro MODIF-Y studies, which continue to support a hypothesis that not all IL-23 inhibitors are the same by demonstrating a differentiated binding mechanism for TREMFYA® (guselkumab) from risankizumab. Findings show that guselkumab is able to dose-dependently bind to CD64+a myeloid cells,1 the predominant source of IL-23-driven inflammation in the gut.2,b Data comprise one of Janssen’s 22 oral and poster presentations at the 18th Congress of the European Crohn’s and Col...
Source: Johnson and Johnson - March 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Isolated Nail Psoriasis May Be Sign of Psoriatic Arthritis Isolated Nail Psoriasis May Be Sign of Psoriatic Arthritis
In the review of 87 cases, the authors documented clinical and histologic features in patients with isolated nail psoriasis.MDedge News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - March 1, 2023 Category: Rheumatology Tags: Dermatology News Source Type: news
Psoriasis Tied to Elevated Risk for Celiac Disease
TUESDAY, Feb. 28, 2023 -- Individuals with psoriasis have double the odds of having celiac disease (CD) versus individuals without psoriasis, according to a research letter published online Feb. 9 in the Journal of the American Academy of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 28, 2023 Category: Pharmaceuticals Source Type: news
Treating Nail Psoriasis: Intralesional Injections and Biologics Treating Nail Psoriasis: Intralesional Injections and Biologics
Systemic therapy is warranted in patients with moderate-to-severe involvement of specific sites or in those refractory to topical therapy, according to Dr April Armstrong.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 24, 2023 Category: Dermatology Tags: Dermatology News Source Type: news
Several Approaches to Psoriasis Treatment in the Future Explored Several Approaches to Psoriasis Treatment in the Future Explored
The development of oral biologics and early aggressive treatment to change the course of the disease are among the possibilities, according to Andrew Blauvelt, MD, MBA.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 22, 2023 Category: Dermatology Tags: Dermatology News Source Type: news
